Wensen JIN, Zhaolu KONG, Zhifen SHEN, et al. Regulation of the radiosensitivity of tumor cells through HIF-1α dependent intracellular redox status after fractionated radiation. [J]. Nuclear Science and Techniques 21(5):294-301(2010)
Wensen JIN, Zhaolu KONG, Zhifen SHEN, et al. Regulation of the radiosensitivity of tumor cells through HIF-1α dependent intracellular redox status after fractionated radiation. [J]. Nuclear Science and Techniques 21(5):294-301(2010) DOI： 10.13538/j.1001-8042/nst.21.294-301.
Regulation of the radiosensitivity of tumor cells through HIF-1α dependent intracellular redox status after fractionated radiation
Tumor cells often develop resistance to radiotherapy by fractionated radiation possibly due to the heterogeneity and hypoxia in tumor tissue. However, the mechanism of refractory effect remains unclear. In the present study, a radioresistant variant HepG2/R60 cell line was isolated from human HepG2 cells by repeated exposure to radiation. The results showed that, after irradiation, the higher survival rate was in HepG2/R60 cells compared to parental cells. Hypoxia treatment could further increase the radioresistance of HepG2/R60 cells concomitant with high level of intracellular GSH and overexpression of HIF-1α. When hypoxic HepG2/R60 cells were pretreated with BSO, a GSH depleter, the refractory response was significantly reduced showing a decrease in intracellular GSH level, followed by the suppression of HIF-1α in hypoxic cells. Subsequent study found that the level of BCL-2 was down-regulated, targeted by HIF-1 prompting transcription in hypoxic cells. The effect of HIF-1α on the radiosensitivity of hypoxic cells was confirmed using YC-1, a specific inhibitor of HIF-1α. Consequently, our results suggest that the radiosensitivity of tumor cells might be regulated by fractionated radiation, and the radioresistance of cells induced by repeated exposure, under hypoxic condition, could be correlated with overexpression of HIF-1α dependent on the alteration of intracellular GSH contents.
RadiationHypoxia inducible factor-1αRadiosensitivityReduced glutathioneRedox status
Rosen E M, Fan S, Rockwell S, et al. Cancer Invest, 1999, 17: 56-72.
Withers H R. Acta Oncol, 2000, 39: 569-577.
Erridge S C, Gaze M N, Price A, et al. Clin Oncol, 2005, 17: 61-67.
Yau T K, Sze W M, Lee W M, et al. Head Neck, 2004, 26: 1024-1030.
Yaromina A, Krause M, Thames H, et al. Radiother Oncol, 2007, 83: 304-310.
Chan N, Koritzinsky M, Zhao H, et al. Cancer Res, 2008, 68: 605-614.
Husbeck B, Peehl D M, Knox S J. Free Radic Biol Med, 2005, 38: 50-57.
Xu Q Y, Gao Y, Liu Y, et al. Chin Med J. 2008, 121: 1830-1837.
Ridder M D, Verellen D, Verovski V, et al. Nitric Oxide, 2008, 19: 164-169.
He F, Li L, Kim D, et al. Cancer Res, 2007, 67: 634-642.
Newcomb E W, Lymberis S C, Lukyanov Y, et al. Cell Cycle, 2006, 5: 93-99.
Harada H, Itasaka S, Zhu Y, et al. Br J Cancer. 2009, 100: 747-757.
Kizaka K S, Itasaka S, Zeng L, et al. Clin Cancer Res, 2009, 5: 3433-3441.
Bruick R K, Mcknight S L. Science, 2001, 294: 1337-1340.
Conaway R C, Brower C S, Conaway J W. Science, 2002, 296: 1254-1258.
Semenza G L. Nat Rev Cancer, 2003, 3: 721-732.
Pore N, Gupta A K, Cerniglia G J, et al. Cancer Res, 2006, 66: 9252-9259.
Sullivan R, Graham C H. Mol Cancer Ther, 2009, 8: 1702-1713.
Unruh A, Ressel A, Mohamed H G, et al. Oncogene, 2003, 22: 3213-3220.
Aebersold D M, Burri P, Beer K T, et al. Cancer Res, 2001, 61: 2911-2916.
Koukourakis M I, Giatromanolaki A, Sivridis E, et al. Int J Radiat Oncol Biol Phys, 2002, 53: 1192-1202.
Koukourakis M I, Giatromanolaki A, Skarlatos J, et al. Cancer Res, 2001, 61: 1830-1832.
Hui E P, Chan A T, Pezzella F, et al. Clin Cancer Res, 2002, 8: 2595-2604.
Bachtiary B, Schindl M, Potter R, et al. Clin Cancer Res, 2003, 9: 2234-2240.
Madhusoodhanan R, Natarajan M, Veeraraghavan J, et al. J Radiat Res, 2009, 50: 311-324.
Chen H, Chow P H, Cheng S K, et al. J Androl, 2003, 24: 704-711.
Griffith O W, Mulcahy R T. Adv Enzymol Relat Areas Mol Biol, 1999, 73: 209-267.
Tiwari P, Kumar A, Balakrishnan S, et al. Mutat Res, 2009, 676: 62-68.
Brouazin J V, Guitton N, Legué F, et al. Anticancer Res, 2002, 22: 257-262.
Geng C X, Zeng Z C, Wang J Y, et al. Docetaxel shows radiosensitization in human hepatocellular carcinoma cells. World J Gastroenterol, 2005, 11: 2990-2993.
Moeller B J, Cao Y, Li CY, et al. Cancer Cell, 2004, 5: 429-441.
Sun H L, Liu Y N, Huang Y T, et al. Oncogene, 2007, 26: 3941-3951.
Kumar M, Samarth R, Kumar M, et al. Evid Based Complement Alternat Med, 2007, 4: 343-350.
Di Toro C G., Di Toro P A, Zieher L M, et al. Neurotoxicology, 2007, 28: 555-561.
Srinivasan M, Rajendra P N, Menon V P. Mutat Res, 2006, 611: 96-103.
Haddad J J. Cell Signal. 2002, 14: 879-897.
Tani M, Goto S, Kamada K, et al. Jpn J Cancer Res, 2002, 93: 716-722.
Haddad J J. Cell Signal, 2002, 14: 799-810.
Teshima K, Yamamoto A, Yamaoka K, et al. Int J Radiat Biol, 2000, 76: 1631-1639.
Morales A, Miranda M, Sanchez-Reyes A, et al. FEBS Lett, 1998, 427: 15-20.